Information, Год журнала: 2025, Номер 16(3), С. 215 - 215
Опубликована: Март 11, 2025
As yet, there is no systematic review focusing on benefits and issues of commercial deep learning-based auto-segmentation (DLAS) software for prostate cancer (PCa) radiation therapy (RT) planning despite that NRG Oncology has underscored such necessity. This article’s purpose to systematically DLAS product performances PCa RT their associated evaluation methodology. A literature search was performed with the use electronic databases 7 November 2024. Thirty-two articles were included as per selection criteria. They evaluated 12 products (Carina Medical LLC INTContour (Lexington, KY, USA), Elekta AB ADMIRE (Stockholm, Sweden), Limbus AI Inc. Contour (Regina, SK, Canada), Manteia Technologies Co. AccuContour (Jian Sheng, China), MIM Software ProtégéAI (Cleveland, OH, Mirada Ltd. DLCExpert (Oxford, UK), MVision.ai Contour+ (Helsinki, Finland), Radformation AutoContour (New York, NY, RaySearch Laboratories RayStation Siemens Healthineers AG AI-Rad Companion Organs RT, syngo.via Image Suite DirectORGANS (Erlangen, Germany), Therapanacea Annotate (Paris, France), Varian Systems, Ethos (Palo Alto, CA, USA)). Their results illustrate can delineate organs at risk (abdominopelvic cavity, anal canal, bladder, body, cauda equina, left (L) right (R) femurs, L R pelvis, proximal sacrum) four clinical target volumes (prostate, lymph nodes, bed, seminal vesicle bed) clinically acceptable outcomes, resulting in delineation time reduction, 5.7–81.1%. Although recommended each centre perform its own prior implementation, seems more important due methodological respective single studies, e.g., small dataset used, etc.
Язык: Английский